Related Experiment Video

Updated: Sep 25, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat

Yves Lamberty1, Doru Georg Margineanu, Donald Dassesse

  • 1UCB Pharma, Preclinical CNS Research, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium. yves.lamberty@ucb-group.com

Pharmacological Research
|June 12, 2003
PubMed

Insights

H3 receptor agonists, like immepip, reduce brain histamine release but do not significantly induce sleep. This study questions the hypnotic potential of these compounds for sleep disorders.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Sleep Medicine

Background:

  • Presynaptic H3 receptors regulate brain histamine synthesis and release.
  • Histamine plays a role in controlling the sleep/wake cycle.
  • H3 receptor agonists are hypothesized to promote sleep by reducing histamine levels.

Purpose of the Study:

  • To investigate the effects of a selective H3 receptor agonist, immepip, on sleep/wake phases in rats.
  • To determine if reduced cortical histamine release correlates with sleep-promoting effects.

Main Methods:

  • Administration of immepip (5 or 10 mg kg(-1)) via intraperitoneal injection in Sprague-Dawley rats.
  • Measurement of cortical histamine efflux using in vivo microdialysis.
  • Assessment of sleep/wake phases (EEG/EMG recordings) during the dark phase.

Main Results:

  • Immepip significantly decreased cortical histamine efflux at the tested doses.
  • No significant impact on active awake, drowsiness, or slow wave sleep phases was observed.
  • A slight but significant decrease in sleep onset latency was noted.

Conclusions:

  • A substantial reduction in cortical histamine release by H3 receptor agonists does not necessarily translate to significant sleep induction.
  • The hypnotic potential of H3 receptor agonists may be limited.
  • Further research is needed to understand the complex role of H3 receptors in sleep regulation.

More Related Videos

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture09:06

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...